glp-1 and afib Can receptor agonists help reduce risk? While traditionally used for type 2 diabetes weight loss, GLP-1 RAs may offer benefits in atrial remodeling and AFib risk reduction. As cardiometabolic Complementary Yet Distinct Roles of

JavaScript is disabled In order to continue, we need to verify that you're not a robot

Next-generation compounds like retatrutide may offer additional options as they move through the approval pipeline

Schedule a free consultation today, and our medical team will support you in reaching your weight loss goals with ease

Donna Ryan, an obesity medicine specialist at Pennington Biomedical Research Center

George now have access to physician-led weight loss care they can trust

ACT 2: Tirzepatide (Mounjaro & Zepbound) More Flexibility, Same Discipline Tirzepatide is a dual GIP/GLP-1 receptor agonist, making it pharmacologically distinct from semaglutide